| Market Capitalization (Millions $) |
1,618 |
| Shares
Outstanding (Millions) |
72 |
| Employees |
677 |
| Revenues (TTM) (Millions $) |
329 |
| Net Income (TTM) (Millions $) |
-29 |
| Cash Flow (TTM) (Millions $) |
76 |
| Capital Exp. (TTM) (Millions $) |
8 |
Veracyte Inc
Veracyte Inc. is a leading genomic diagnostics company that provides solutions to patients who suffer from thyroid and lung diseases, as well as other types of cancer. The company is headquartered in South San Francisco, California, and has additional offices in Austin, Texas, and Italy.
Veracyte is focused on developing and commercializing genomic tests that enable doctors to diagnose and monitor patients with complex diseases more accurately. The company's products are based on RNA sequencing technology and genomic analysis, which help provide more precise information about the underlying genetic causes of disease.
Veracyte's flagship product, the Afirma Thyroid FNA Analysis, is used to diagnose thyroid nodules, which are a common medical problem that often requires further investigation to determine if they are benign or malignant. The Afirma Thyroid FNA Analysis delivers a diagnostic yield of up to 95%, allowing for more accurate diagnoses and reducing the number of unnecessary surgeries.
In addition to its thyroid diagnostic product, Veracyte also offers a lung cancer diagnostic test called the Percepta Bronchial Genomic Classifier. This test is used to diagnose early-stage lung cancer in patients who have received inconclusive biopsy results. It uses genomic analysis to identify the presence of cancer cells in the lungs, enabling doctors to start treatment at an earlier stage.
Veracyte's genomic testing products have won multiple awards and have been validated by leading medical institutions, such as the MD Anderson Cancer Center and the National Cancer Institute. The company has also secured partnerships with large pharmaceutical companies, such as Roche, to develop diagnostic tests for a wide range of diseases.
Along with its focus on developing genomic tests, Veracyte is also committed to advancing the field of genomic medicine through research and collaborations with academic institutions. The company has published numerous scientific papers and presented findings at major industry conferences.
Veracyte has a strong financial position, with significant revenues and ongoing growth. The company's market cap surpasses $3 billion, and its stock enjoys a consistently solid investor following. Its leadership team comprises experienced executives and key opinion leaders appointed from top-tier organizations to ensure consistent quality results and steady progress.
overall, Veracyte is seen an innovative, reliable, and valuable partner for patients and practitioners seeking more accurate diagnostic tools based on genomic technology.
Company Address: 6000 Shoreline Court South San Francisco 94080 CA
Company Phone Number: 243-6300 Stock Exchange / Ticker: NASDAQ VCYT
| VCYT is expected to report next financial results on November 02, 2023. |
|
|
